Clinical trials: Upper Extremity Pain Chronic

Systemic Juvenile Idiopathic Arthritis

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

• Completed
• Age: 2 to 19 years
• Phase 3
• Results posted

This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…

Trial name

NCT02396212

Testing

Canakinumab

Where

7 sites in Japan

Volunteers

19 people

Sponsor

Novartis Pharmaceuticals